Dr. Vince Bertucci’s CV Summary

1992 – 1995 

Dermatology, University of Toronto, FRCPC, DABD 

1989 – 1992 

Internal Medicine, University of Toronto, FRCPC 

1985 – 1989 

Doctor of Medicine (M.D.), Faculty of Medicine, University of Toronto. 

1983 – 1985 

Physiology Programme, Faculty of Arts and Science, University of Toronto. 

1978 – 1983 

Dante Alighieri Academy High School, Toronto, Ontario Secondary School Honour Graduation Diploma 

07/1995 – 06/1996 

Fellowship, Dermatologic Surgery, University of Toronto

07/1994 – 06/1995 

Chief Resident, Dermatology, University of Toronto 

07/1992 – 06/1994 

Resident, Dermatology, University of Toronto 

07/1989 – 06/1992 

Resident, Internal Medicine, University of Toronto 

2000 – Present 

Founder & Medical Director, Bertucci MedSpa, Woodbridge, Ontario, Canada 

2001 – 2003 

Medical Consultant, Ventana Clinical Research Corporation, Toronto, Ontario, Canada 

1996 – 2000 

Dermatologist, Group Practice, Toronto, Ontario, Canada 

1997 – 1998 

Consultant Dermatologist, Meaford General Hospital, Meaford, Ontario, Canada 

2010 – Present 

Co-Director, Dermatologic Laser Surgery and Aesthetic Dermatology Fellowship, University of Toronto, Canada 

1997 – Present 

Instructor, Division of Dermatology, Department of Medicine, University of Toronto, Canada 

1996 – Present 

Consultant Dermatologist, Women’s College Hospital, University of Toronto, Canada 

2011 – 2016 

Examiner, Royal College of Physicians and Surgeons of Canada. 

1997 – 2008 

Co-Director, Undergraduate Dermatology, University of Toronto, Canada 

2021 

Principal Investigator: A randomized, evaluator-blinded, parallel group, no treatment controlled, multicenter study to evaluate effectiveness and safety of GP0109 for augmentation and correction of retrusion in the chin region. Phase 3. Sponsor: Q-Med AB / Galderma. 

2021 

Principal Investigator: A Study Comparing Hyaluronic Acid Effectiveness & Evaluating Cheek Results with Restylane. Phase 4. Sponsor: Q-Med AB / Galderma. 

2020 – 2021 

Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination (REDADY-3). Phase 3. Sponsor: Galderma. 

2019 – 2021

Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines with or without Concurrent Treatment of Lateral Canthal Lines. Phase 3. Sponsor: Allergan Inc

2019 – 2020 

Principal Investigator: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX^® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence. Sponsor: Allergan Inc. 

2019 – 2020 

Principal Investigator: Post Marketing study to evaluate lip enhancement, naturalness and partner/subject satisfaction after treatment with Restylane Kysse. Phase 4. Sponsor: Galderma. 

2018 – 2020  

Principal Investigator: Canada Global HARMONY: Prospective, Multi-site, Study to Evaluate Subject Satisfaction with Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment. Phase 4. Sponsor: Allergan Inc. 

2019 – 2020  

Principal Investigator:  A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for the Treatment of Dynamic Forehead Lines (Frontalis) Following Glabellar Line Injections. Phase 2a. Sponsor: Revance Therapeutics Inc. 

2017 – 2018 

Principal Investigator: An Open Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN LABEL SAFETY). Phase 3. Sponsor: Revance Therapeutics Inc. 

2016 – 2017 

Principal Investigator: A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-2). Phase 3. Sponsor: Revance Therapeutics Inc. 

2016 

Principal Investigator: A Multi-Center Study to Evaluate the Perception of Facial Expressions Following Correction of Wrinkles and Folds in the Lower Face using Emervel^® Classic Lidocaine and Emervel^® Deep Lidocaine. Phase 4. Sponsor: Galderma Laboratories, L.P. 

2016 

Principal Investigator: BOTOX^® Treatment of Masseter Muscle Hypertrophy. Phase 3. Sponsor: Allergan Inc. 

2015 – 2016 

Principal Investigator: Evaluation of the Merz Jawline Grading Scale Following Radiesse (+)^® Correction of Subcutaneous Volume Loss and Contour Deficits of the Jawline – a Canadian Pilot Study. Sponsor: Merz North America, Inc. 

2015 

Principal Investigator: A Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines. Phase 2. Sponsor: Revance Therapeutics Inc. 

2013 – 2014 

Principal Investigator: OnabotulinumtoxinA in the Treatment of Forehead Lines. Sponsor: Allergan Inc. 

2013 – 2014 

Principal Investigator: A Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled Study of Subject Satisfaction of BOTOX^® Cosmetic Treatment in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines). Sponsor: Allergan Inc. 

2012 – 2013 

Principal Investigator: Evaluation of Pain with the Use Of Radiesse^® with Lidocaine for the Treatment of Nasolabial Folds. Sponsor: Merz Aesthetics, Inc. 

2012 – 2013 

Principal Investigator: Multicenter, randomized, double-blind, placebo-controlled, Phase 3 study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area. 

Sponsor: Kythera Biopharmaceuticals, Inc. 

2011 – 2012 

Principal Investigator: Efficacy and Safety comparison of adapalene 0.1% / benzoyl peroxide 2.5% gel associated with 200 mg doxycycline capsules versus vehicle gel associated with isotretinoin capsules in the treatment of severe acne. Sponsor: Galderma Research & Development.

2011 – 2012 

Principal Investigator: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Extension Study to Evaluate the Safety and Efficacy of BOTOX^® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines). Sponsor: Allergan Inc. 

2011 

Principal Investigator: Evaluation of Pain with the Use Of Radiesse^® with Lidocaine for the Treatment of Nasolabial Folds. Sponsor: Merz Aesthetics, Inc. 

2010 – 2011 

Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of BOTOX^® Cosmetic (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines). Sponsor: Allergan Inc. 

2010 – 2011 

Principal Investigator: A Randomized, Single-Blind Study Evaluating the Safety and Effectiveness of the LipoSonix^™ System when Treating Adipose Tissue at Single and Multiple Focal Depths with the Same Energy Level after One or Two Treatments. Sponsor: Medicis Technologies Corporation. 

2010 – 2011 

Principal Investigator: An Open Label, Multicenter Study of the Safety and Efficacy of Perlane-L^™ Injectable Gel in the Correction of Midface Volume Loss and/or Midface Contour Deficiency. Sponsor: Medicis Global Services Corporation. 

2003 

Subinvestigator: Canadian Phase 4 Open-Label Multi-Centre Study of Botox for Treatment of Patients with Axillary Hyperhidrosis 

2001 – 2002 

Subinvestigator: An Open-Label, Multi-Centre Study of the Efficacy of Various Treatment Schedules of VAS972 in Patients with Moderate to Severe Psoriasis. Sponsor: Vasogen Inc.

2001 – 2002 

Subinvestigator: A 12-week, randomised, double-blind, placebo-controlled, multi-centre, parallel-group, dose-finding study to determine the dose response, safety and tolerability of three doses (10, 20, 30 mg b.i.d.) of SDZ ASM 981 tablets in subjects with atopic dermatitis.  Phase IIb.  Sponsor: Novartis Pharma AG 

January 12, 2002 

How to be a Good Clinical Trials Investigator, Women’s College Hospital, Division of Dermatology, University of Toronto, Canada 

June 2, 2001 

Clinical Trials Workshop, Dermatology Nurses Association, Toronto, Canada 

2014 

Editorial: Innovations in Aesthetic Dermatology 2014, CDA eBulletin, December 2014 Issue 

2012 

Editorial: The Evolving Aesthetic Medicine Landscape, The Chronicle of Cosmetic Medicine + Surgery, Summer 2012 Issue 

2012 

Guest Editor, The Chronicle of Cosmetic Medicine + Surgery, Summer 2012 Issue 

2011 – Present 

Editorial Board, The Chronicle of Cosmetic Medicine + Surgery 

2010 – Present 

Contributing Editor, Dermatologic Surgery 

2009 – Present 

Contributing Editor, Journal of Cutaneous Medicine & Surgery 

October 2009 

Guest Editor, Canadian Dermatology Association Bulletin, Dermatologic Surgery Issue 

June 2008 

Guest Editor, Canadian Dermatology Association Bulletin, Dermatologic Surgery Issue 

2020 

President’s Award, American Society for Dermatologic Surgery. 

2009 

Canadian Dermatology Association, Young Dermatologists’ Volunteer Award. 

2008 

University of Toronto, Division of Dermatology, Undergraduate Dermatology Education Award. 

2002 

Nominated for Dermatology Teacher of the Year Award, Dermatology Residency Program, University of Toronto. 

1996 

F.M. Hill Research Award, Women’s College Hospital, Toronto. 

1987-1988 

Honours Standing, Faculty of Medicine, University of Toronto 

1985 

National Science and Engineering Research Council of Canada Scholarship

1983-1985 

Faculty Scholar, University of Toronto, Canada. 

1983-1985 

Admission Scholarship, St. Michael’s College, University of Toronto, Canada. 

Sep 11-12, 2021 

Director, Advanced Injection Techniques Course, American Society for Dermatologic Surgery, New York City, NY 

Mar 17, 2021 

Cardiopulmonary Resuscitation (CPR) Certification, Canadian Red Cross 

2020 – 2021 

Vice President, American Society for Dermatologic Surgery 

2020 

Member, Taskforce on Guidance Regarding SARS-CoV-2 mRNA Vaccine Side Effects in Dermal Filler Patients, American Society for Dermatologic Surgery.

2021 – 2023 

Chair, Membership Committee, American Academy of Dermatology. 

Oct 11, 2020 

Director, Facial Assessment and Fillers Course, 

ASDS Annual Meeting. [Virtual]. 

Sep 11-13, 2020 

Director, Advanced Anatomy and Injection Techniques Course, American Society for Dermatologic Surgery. 

2020 – 2021 

Member, Taskforce on Guidance for Cosmetic Dermatology Practices During COVID-19, American Society for Dermatologic Surgery and American Society for Laser Medicine & Surgery.

2019 – 2021 

Deputy Chair, Membership Committee, American Academy of Dermatology. 

2019 – 2020 and 2013 – 2014 

Mentor, Future Leaders Network, American Society for Dermatologic Surgery. 

2017 – 2020 

Member, Board of Directors, American Society for Dermatologic Surgery. 

2019

Chair, Task Force on Educating Clinical Staff at the Annual Meeting, American Society for Dermatologic Surgery.

2019– and 2011–15

Executive Committee, Toronto Dermatological Society 

2017 – 2019 

Chair, Leadership Development Work Group, American Society for Dermatologic Surgery. 

Nov 23-24, 2019 

Director, Advanced Injection Techniques: Maximize Safety and Minimize Complications Course, American Society for Dermatologic Surgery, New York City, NY. 

October 24, 2019 

Director, Soft Tissue Fillers: Advanced Video Instruction with Panel Discussion, American Society for Dermatologic Surgery Annual Meeting, Chicago, IL

March 4, 2019 

Director, Soft Tissue Fillers: Video Instruction and Live Panel Discussion. American Academy of Dermatology Annual Meeting, Washington, DC. 

October 13, 2018 

Director, Facial Finesse Part 2: Gender and Ethnic Analysis and Treatment. American Society for Dermatologic Surgery Annual Meeting, Phoenix, AZ.